Investing.com - Financial Markets Worldwide
⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Nigeria warns on oxygen supplies, dysfunctional labs in tackling COVID

Published 29/12/2020, 19:19
© Reuters.

ABUJA, Dec 29 (Reuters) - Nigeria faces oxygen supply
challenges to treat coronavirus patients in parts of the country
and unacceptable laboratory delays as case numbers rose to the
highest recorded in a single week, health authorities said on
Tuesday.
The new warnings from Nigerian officials come as the
resurgent virus strikes across much of the world, bringing
greater case loads and hospitalisations.
"There is an on-going review of the chain for the supply of
medical oxygen for our medical facilities across the nation,"
said Boss Mustapha, chairman of Nigeria's coronavirus task
force, naming the capital of Abuja as an area of concern.
Labs' "inability to function optimally has resulted in
unacceptable levels of delay in receiving results," he added,
calling on Nigeria's state governments to reopen all
laboratories, ensure prompt testing and keep open treatment
centres. "This is not helping our national response."
Nigeria, Africa's most populous country, has recorded few
coronavirus cases compared to others on the continent. Since the
beginning of the pandemic, officials count 84,811 as of Tuesday
evening, with 1,264 deaths.
South Africa, with a population little more than a quarter
of Nigeria's, has recorded 1 million cases.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.